Abstract / Summary
Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies with generally poor prognosis, raising a continued interest in novel therapeutic targets. The TAM-family receptor tyrosine kinase AXL has been proposed as a therapeutic target across several cancer types, including STS. Here we revisit the clinical relevance of AXL in STS by combining in silico analyses with functional and transcriptomic characterisation of two representative AXL inhibitors, dubermatinib and bemcentinib, in the HT-1080 and SK-LMS-1 STS-derived cell models. STS ranked among the tumour types with the highest median AXL mRNA expression across The Cancer Genome Atlas, yet AXL expression was not associated with patient survival. Both dubermatinib and bemcentinib reduced cell viability and induced apoptosis but, unexpectedly, shRNA-mediated AXL knockdown failed to reproduce the antiproliferative effect of either inhibitor and did not modify cellular sensitivity to drugs treatment. Transcriptomic profiling after AXL genetic knockdown showed weak correlation with drug-induced transcriptional changes, with the large majority of drug-regulated genes being AXL-independent and largely specific to each cell line. Our data indicate that although dubermatinib and bemcentinib show clear antitumour activity in STS models, this activity is largely independent from AXL inhibition, suggesting the rationale for AXL-directed therapy may be reconsidered.